N
DTIL icon

Nuveen’s Precision BioSciences DTIL Stock Holding History

Nuveen’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,010
Closed -$1.56M – 3311
2022
Q1 		$1.56M Buy
17,010
+1,179
+7% +$160K ﹤0.01% 2629
2021
Q4 		$3.52M Buy
15,831
+483
+3% +$135K ﹤0.01% 2293
2021
Q3 		$5.31M Buy
15,348
+9,865
+180% +$3.34M ﹤0.01% 2175
2021
Q2 		$2.06M Sell
5,483
-356
-6% -$107K ﹤0.01% 2696
2021
Q1 		$1.81M Buy
5,839
+730
+14% +$256K ﹤0.01% 2663
2020
Q4 		$1.28M Sell
5,109
-1,727
-25% -$423K ﹤0.01% 2717
2020
Q3 		$1.26M Buy
6,836
+28
+0.4% +$5.57K ﹤0.01% 2587
2020
Q2 		$1.7M Buy
6,808
+633
+10% +$139K ﹤0.01% 2407
2020
Q1 		$1.12M Buy
6,175
+1,222
+25% +$320K ﹤0.01% 2471
2019
Q4 		$2.06M Buy
4,953
+4,500
+993% +$1.41M ﹤0.01% 2408
2019
Q3 		$114K Hold
453
– – ﹤0.01% 3158
2019
Q2 		$180K Buy
+453
New +$182K ﹤0.01% 3189

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Nuveen's DTIL Position: Q2 2022 in Review

Nuveen sold out of Precision BioSciences (DTIL) in Q2 2022, closing a stake of 17,010 shares — an estimated $1.56M sold.

Nuveen first reported a position in DTIL in Q2 2019 and held it in 12 quarters. The position peaked at $5.31M in Q3 2021. 119 funds tracked by Wall St. Rank hold DTIL as of Q2 2022.

  • Nuveen reported no remaining Precision BioSciences position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 17,010 Precision BioSciences shares in Q2 2022, an estimated $1.56M.
  • Nuveen first reported a position in Precision BioSciences in Q2 2019 and held it in 12 quarters.
  • Nuveen's Precision BioSciences position peaked at $5.31M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.